New hope for IBD patients: can a better antibiotic stop c. diff for good?
NCT ID NCT06794944
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two antibiotics, fidaxomicin and vancomycin, to see which one is better at clearing C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 60 adults with IBD will take one of the two antibiotics for 10 days and be followed for 26 weeks. The goal is to find a treatment that reduces C. diff infections and improves IBD symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIOIDES DIFFICILE INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill tame inflammatory bowel disease? early safety trial begins
- Can a mediterranean diet and Time-Restricted eating tame gut inflammation?
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Two-Drug cocktail aims to tame stubborn Crohn's disease
- Dutch hospital data reveals hidden patterns in IBD treatment
- Acupuncture points may signal hidden disease activity